Ascelia Pharma AB

Ascelia Pharma AB is a Swedish biotech company dedicated to developing and commercializing novel drugs for orphan oncology treatments. They focus on addressing unmet medical needs in rare cancer conditions, aiming to improve the lives of patients and offer better treatment options. Their two main drug candidates, Orviglance® and Oncoral, are currently in clinical development. Orviglance® is a liver imaging drug used for MRI, while Oncoral is a novel tablet formulation of the chemotherapy drug irinotecan.

Ascelia Pharma is headquartered in Malmö, Sweden, and is listed on Nasdaq Stockholm. They are committed to building a global life science organization and have a clear development and market pathway for their drugs. The company actively seeks partnerships to further develop and commercialize their products, aiming to make a difference in the lives of people living with cancer.

Ascelia Pharma's website mentions that their head office is in Malmö, Sweden, conveniently located by the Hyllie train station with easy access to Copenhagen and Malmö Central Station. However, there is no specific mention of any job flexibility options like remote work, flexible hours, or part-time arrangements.

Ascelia Pharma AB is a Swedish biotech company focused on developing and commercializing novel drugs for people with rare cancer conditions. Their mission is to be a leader in identifying and bringing to market innovative therapies that address the unmet needs of patients suffering from these often-overlooked cancers. They strive to improve the lives of people living with cancer by offering better treatment options and ultimately enhancing their quality of life and life expectancy.

Ascelia Pharma fosters a culture of integrity, courage, and focus. They value building powerful relationships with mutual respect, adhering to high ethical standards, and working tirelessly to achieve their goals even when it means challenging the status quo. They are devoted to improving the lives of patients and creating value for their stakeholders.

Ascelia Pharma doesn't explicitly mention a diversity, equity, and inclusion (DE&I) program or strategy on their website. However, their emphasis on building "powerful relationships with mutual respect" and a commitment to high ethical standards within their "Our Values" section suggests a potential foundation for fostering an inclusive work environment. Their global headquarters in Malmö, Sweden and US subsidiary in Iselin, NJ, indicate a potential for diverse talent and perspectives within the company.